Related Experiment Videos

Thiol-containing compounds inhibit the production of monocyte/macrophage-derived angiogenic activity

A E Koch1, J C Burrows, P J Polverini

  • 1Department of Medicine, Northwestern University Medical School, Chicago, IL 60611.

Agents and Actions
|November 1, 1991
PubMed

Insights

Thiol-containing compounds (TCCs) inhibit macrophage-mediated angiogenesis, a key factor in rheumatoid arthritis. This finding offers insight into how gold compounds treat rheumatoid arthritis by affecting macrophage activity.

Area of Science:

  • Immunology
  • Rheumatology
  • Biochemistry

Background:

  • Macrophage (M phi)-mediated angiogenesis is crucial in rheumatoid arthritis pathogenesis.
  • Gold sodium thiomalate, a rheumatoid arthritis therapeutic, inhibits M phi-derived angiogenic activity.

Purpose of the Study:

  • To elucidate the mechanism by which thiol-containing compounds (TCCs) inhibit M phi-mediated angiogenesis.
  • To investigate the effect of TCCs on M phi and human monocyte-derived angiogenic activity.

Main Methods:

  • Assessing the angiogenic potential of monocyte/M phi conditioned media in rat corneas.
  • Treating elicited mouse peritoneal M phi and lipopolysaccharide-stimulated human monocytes with TCCs.
  • Measuring tumor necrosis factor-alpha (TNF-alpha) levels in conditioned media.

Main Results:

  • TCCs significantly inhibited the production of M phi-derived angiogenic activity.
  • TCCs did not affect existing angiogenic factors or the rat cornea's microvasculature.
  • Tumor necrosis factor-alpha (TNF-alpha) levels remained unchanged, indicating TCCs target production, not specific mediators.

Conclusions:

  • Thiol-containing compounds (TCCs) are potent inhibitors of macrophage-mediated angiogenic activity production.
  • This inhibitory action on macrophages may contribute to the therapeutic mechanism of gold compounds in rheumatoid arthritis.

Related Concept Videos